Dementia Drug’s Hidden Stroke Danger

A medical professional holding a brain model in one hand and a yellow supplement capsule in the other

A common dementia drug spikes stroke risk even in patients doctors once deemed completely safe.

Story Highlights

UK study of 165,000 dementia patients shows risperidone raises stroke rates across all groups, including low-risk ones.
Stroke incidence hit 2.9 per 1,000 person-years on the drug versus 2.2 without, even in those with no prior history.
Risperidone remains the only UK-licensed antipsychotic for severe dementia agitation, despite NHS 6-week limit often ignored.
Experts call for personalized prescribing and better monitoring to balance agitation relief against hidden dangers.

Study Uncovers Uniform Stroke Risk in Dementia Patients

Researchers analyzed NHS records from 2004 to 2023 covering over 165,000 dementia patients. Risperidone, prescribed for severe agitation, increased stroke rates in every subgroup. Patients with prior strokes faced 22.2 events per 1,000 person-years on the drug compared to 17.7 without it. Those without prior strokes saw 2.9 versus 2.2. Short-term use up to 12 weeks showed the highest risk elevation. This real-world data challenges prior assumptions of safer profiles in low-risk groups.

Risperidone’s Role in Dementia Care

Risperidone targets dopamine and serotonin receptors. Approved since the 1990s for psychiatric conditions, it serves as the sole UK-licensed option for dementia agitation. About 50% of dementia patients experience severe agitation unresponsive to non-drug measures, particularly in care homes. NHS guidelines cap use at 6 weeks for extreme cases, yet doctors frequently extend prescriptions with spotty monitoring. Regulatory alerts since the 2000s warned of cerebrovascular risks in elderly users.

Key Players Driving the Research

Brunel University London led the study, published October 2025 in The British Journal of Psychiatry. Joshua Choma and colleagues crunched the anonymized NHS data. Dr. Byron Creese, from Brunel’s College of Health, Medicine and Life Sciences, commented on findings. NHS provided the records and sets prescribing rules. Janssen manufactures Risperdal, the brand-name version. Researchers prioritize evidence-based safety; NHS weighs symptom control against harm; families face tough choices on agitation versus stroke threats.

NHS policymakers hold prescribing power. Academics like Creese push for policy shifts through public advocacy. Care homes depend heavily on risperidone amid few alternatives. No conflicts of interest surfaced in the reports.

165,000 dementia patients reveal hidden stroke risk from common drug

A massive UK study of more than 165,000 dementia patients has uncovered troubling new evidence about risperidone, a commonly used drug for severe agitation. Researchers found the antipsychotic increases stroke…

— The Something Guy 🇿🇦 (@thesomethingguy) March 9, 2026

Expert Calls for Practice Changes

Dr. Creese stated the evidence eliminates so-called safe patient groups. He urges person-centered guidance tailored to individual risks and real-world factors. Study authors highlight clearer data for decisions, separating drug effects from baseline vulnerabilities. Consensus holds that risperidone elevates risk uniformly, though severe cases may justify use after doctor-family discussions.

No new UK-licensed alternatives exist. Ongoing NHS use often exceeds guidelines. Media coverage in late 2025 amplified calls for updates, but no regulatory moves followed yet.

Implications for Patients and Caregivers

Dementia patients and carers bear the brunt, with agitation distressing everyone involved. Short-term, doctors may prescribe less, fostering shared decisions. Long-term, expect guideline overhauls, non-drug pushes, and tighter protocols. Economically, fewer prescriptions could cut stroke care costs; socially, better info eases carer loads; politically, NHS faces pressure for dementia safeguards. Globally, this may reduce antipsychotic dependence in elder care and spark safer treatment research.